NTRX-07 is under clinical development by NeuroTherpia and currently in Phase I for Alzheimer’s Disease. According to GlobalData, Phase I drugs for Alzheimer’s Disease have a 64% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how NTRX-07’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
NTRX-07 is under investigation for the treatment of Alzheimer's disease complex regional pain syndrome (CRPS) and neuropathic pain. NTRX-07 administered through oral route. The drug candidate is a piperidine derivative. It targets cannabinoid (CB2) receptors.
For a complete picture of NTRX-07’s drug-specific PTSR and LoA scores, buy the report here.